33%
Menu
Envisionit Deep AI™ is committed to fighting the impact of COVID-19.
We’ve developed RADIFY™ to enable radiologists to diagnose more images, more consistently and in less time – whilst prioritising care for people who need it most.
In response to the COVID-19 outbreak, we would like to offer RADIFY™ to any public and private organisation using X-ray in the identification and treatment of COVID-19 pneumonia.
A chest X-Ray is the first line of investigation for pneumonia. It’s the most readily available, quick and cost-effective imaging tool for the diagnosis of pneumonia – the number one killer of patients with COVID-19 and TB.
RADIFY™ detects 20 major abnormalities on chest X-rays – including TB and COVID 19 pneumonia related pathologies. It can label and prioritise over 2000 x-rays per minute.
A chest X-Ray is the first line of investigation for pneumonia. It’s the most readily available, quick and cost-effective imaging tool for the diagnosis of pneumonia – the number one killer of patients with COVID-19 and TB.
RADIFY™ detects 20 major abnormalities on chest X-rays – including TB and COVID 19 pneumonia related pathologies. It can label and prioritise over 2000 x-rays per minute.
A 76-year-old male presented with chest pain and dyspnoea. Patchy infiltrates in the right and left upper zones with air space opacification noted in the right midzone and left lower zone. RADIFY™ has detected the lesions with bounding boxes in the region of interest.
Result: High probability of pneumonia
A 76-year-old male presented with chest pain and dyspnoea. Patchy infiltrates in the right and left upper zones with air space opacification noted in the right midzone and left lower zone. RADIFY™ has detected the lesions with bounding boxes in the region of interest.
Result: High probability of pneumonia
In 2019, an estimated 10 million people fell ill with tuberculosis (TB) worldwide, of which, 1.2 million where children, yet TB is curable and preventable.
An estimated 1.4 million fewer people received care for tuberculosis (TB) in 2020 than in 2019, according to preliminary data compiled by the World Health Organization (WHO) from over 80 countries- a reduction of 21% from 2019.
The countries with the biggest relative gaps were Indonesia (42%), South Africa (41%), Philippines (37%) and India (25%).
RADIFY™ for TB , identifies pathologies on chest x-rays and triages the patients with high, intermediate and low probability of TB in children and adults.
WHO now recommends CAD with chest x-rays to fight tuberculosis!
A 10 year old child with high probability of Tuberculosis detected by RADIFY™.
Bilateral lymphadenopathy and bi-basal areas of confluent consolidation highlighted by RADIFY™.
An innovative medical technology company using Artificial Intelligence to transform medical imaging diagnosis.
Trained and validated by radiologists for medical practitioners, our products detect and highlight abnormalities on medical imaging.
This product is licensed with SAHPRA as a Class A Medical Device as a medical image management system application software. This product is for professional and academic use.
2020-2022 © Envisionit Deep AI (Pty) Ltd. 2019/038117/07. All Rights Reserved. Terms & Conditions Apply.
Data privacy is a human right. Envisionit Deep AI™ is committed to the privacy and confidentiality of information provided to us in compliance with all relevant legislation, including the Protection of Personal Information Act, 2013 (“POPI”) and General Data Protection Regulation (GDPR) (EU) 2016/679.
Welcome! We use cookies – Cookies tell us which parts of our websites you visited, help us measure the effectiveness of ads and web searches, and give us insights into user behaviour, so that we can improve our communications and products. Learn more about this in our Privacy Policy.